Reuters: FDA staff wants input on Amgen clot drug risks

[NaDiNe]

FDA staff wants input on Amgen clot drug risks
      

WASHINGTON (Reuters) - U.S. drug reviewers will ask an advisory panel for input on five potential safety concerns with an experimental Amgen Inc medicine for a blood clotting disorder, documents released on Monday said.
<p>You are not allowed to view links. Register or Login</p><div class="feedflare">
You are not allowed to view links. Register or Login You are not allowed to view links. Register or Login You are not allowed to view links. Register or Login
</div><img src="You are not allowed to view links. Register or Login" height="1" width="1"/>
      

You are not allowed to view links. Register or Login